CYP2D6 genotype and tamoxifen response by Rae, James M et al.
Available online http://breast-cancer-research.com/contents/7/5/E6
We read with interest the article by Wegman and coworkers
[1] entitled ‘Genotype of metabolic enzymes and the benefit
of tamoxifen in postmenopausal breast cancer patients’. The
authors conducted a retrospective analysis of a tamoxifen
adjuvant clinical trial and reported that a small subset of
patients with estrogen receptor (ER)-positive breast cancer
treated with tamoxifen who carried the CYP2D6*4 variant
allele did significantly better than patients with the same
variants not treated with tamoxifen.
We believe that these data are actually not in contrast to data
presented by us and others, as the authors suggest. Rather, we
believe that alternative interpretations of the data may shed a
different light on their conclusions. First, it is important to
understand the patients included in this study. They began with
a subset of patients (226/679 [33%]) treated in an adjuvant
tamoxifen trial designed to compare the effects of tamoxifen
(40 mg/day for 2 years) alone or with chemotherapy, and with or
without radiation. Of these, only 112 patients received tamoxifen
and only 71 were ER positive. Thus, only 10.5% of patients in
the overall trial (71/679) were included in this small substudy,
meaning that there is great potential for selection bias.
Initially, the authors did not find a difference in outcome by
CYP2D6*4 genotype, and therefore they compared the
outcomes in patients with at least one CYP2D6*4 allele who
received tamoxifen (n= 24) versus no tamoxifen (n= 23). They
found that patients with the CYP2D6*4 genotype did
significantly better than patients not treated with tamoxifen and
observed a similar trend in women with the SULT1A1*1
homozygous genotype. They concluded that genotyping of these
enzymes may be useful in predicting clinical outcomes and that
their findings were in contrast to the current hypotheses on the
role of metabolic enzymes in tamoxifen activation and inactivation.
We believe the data presented are consistent with our
results, which suggest that CYP2D6 poor metabolizers may
experience less benefit from tamoxifen treatment [2]. It is
expected that ER-positive women treated with tamoxifen will
have better outcomes than ER-positive women treated
without tamoxifen, even if they have one CYP2D6*4 allele,
because this group would not completely eliminate the
benefits of tamoxifen. Indeed, it appears that the data
presented by Wegman and coworkers are consistent with
this hypothesis, albeit the numbers are very small because of
the considerable subsetting and selection.
Our studies have shown that the serum concentration of an
active metabolite of tamoxifen, namely endoxifen, is effected
by CYP2D6 status in a gene dose dependent manner, with
low, intermediate and high concentrations in homozygous
variant, heterozygous and homozygous wild-type patients,
respectively [3,4]. Furthermore, data from a large randomized
trial of postmenopausal women receiving adjuvant tamoxifen
for 5 years [2] indicate that women who are homozygous (but
not heterozygous) for the CYP2D6*4 allele have significantly
worse relapse-free survival and disease-free survivals than do
women who are heterozygous or homozygous for the
common allele. These findings suggest that the outcome of
women with ‘intermediate’ concentrations of endoxifen, as
represented by the heterozygous CYP2D6*4, are no different
than women who carry two wild-type CYP2D6 alleles. This
suggests that the clinical effect of tamoxifen is due to multiple
metabolites, and only when women carry two null CYP2D6
alleles, corresponding to the CYP2D6 poor metabolizer
phenotype, do outcomes deteriorate.
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